Early reperfusion therapy has improved the clinical outcomes of patients with acute myocardial infarction (AMI), but these benefits are limited in some patients by reperfusion injuries. There is now increasing evidence that reactive oxygen species cause reperfusion injury. This study was designed to examine the effects of edaravone, a novel free radical scavenger, in patients with AMI.
Initial AMI patients were randomly assigned to receive 30 mg of edaravone or a placebo intravenously just before reperfusion. We compared infarct size, using serial determination of serum biomarkers and Q wave formations, and the incidence of reperfusion arrhythmia between the groups. Cardiovascular event-free curves were estimated by Kaplan-Meier method. In addition, we determined serum thioredoxin levels, an oxidative stress marker, to assess the antioxidant effect of edaravone.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
104
intravenous administration of 30mg Edaravone just before reperfusion therapy
Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University
Kumamoto, Japan
Cardiac Death
number of cardiac death
Time frame: 415±32 days
Nonfatal Myocardial Reinfarction
number of nonfatal myocardial reinfarction
Time frame: 415days
Refractory Angina Pectoris
number of refractory angina pectoris
Time frame: 415days
Nonfatal Ischemic Stroke
number of nonfatal ischemic stroke
Time frame: 415days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.